Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

To Prevent Drug Shortages, Don't Look To Inspections, FDA Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Agency maintains its inspection policy does not cause or prevent shortages.

You may also be interested in...



Drug Shortages: FDA Says Market Must Reward Production Quality

FDA officials state in journal article that manufacturers are not incentivized to ensure quality and base competition entirely on price.

FDA And Generic Drug Quality: Turning Point, Or Precipice?

OGD Director Geba says generic manufacturers still suffer from extensive quality problems, but GPhA officials argue the industry is doing fine and communications with the agency need to be more uniform.

FDA Spending Less Time On INDs, More On NDAs and BLAs

Five-year averages used in calculations of FY 2013 user fee rates show a decrease in time devoted to INDs and an increase in time spent on NDAs and BLAs. The average submission volume in both categories still increased.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS072675

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel